World of DTC Marketing

MARCH 27, 2022

Mental illnesses are common in the United States. Nearly one in five U.S. adults live with a mental illness (52.9 million in 2020). Mental illnesses include many different conditions that vary in severity, ranging from mild to moderate to severe. Suicidal ideation continues to increase among adults in the U.S. 4.58% of adults report having serious thoughts of suicide, an increase of 664,000 people from last year’s dataset.

Engineer 259

Engineer Doctors Doctor 259

Pharma Mirror

MARCH 27, 2022

BARCELONA, Spain, More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Almirall S.A. (BME: ALM) announced today at the American Academy of Dermatology (AAD) Annual Meeting. Lebrikizumab, an investigational IL-13 inhibitor, also led to clinically meaningful improvements in itch and other important patient-reported outcomes

Dermatology 130

Dermatology Medicine 130

JAMA Internal Medicine

MARCH 27, 2022

This systematic review and meta-analysis of 76 randomized clinical trials examines the effects of glucagon-like peptide-1 receptor agonist use on the risk of gallbladder and biliary diseases.

Clinical Trials 98

Clinical Trials Clinical Trials Trials 98

pharmaphorum

MARCH 27, 2022

Johnson & Johnson is in course for approval of its multiple myeloma CAR-T therapy Carvykti in the EU the next few weeks, after getting a green light from the EMA’s human medicines committee. The CHMP recommended conditional approval for Carvykti (ciltacabtagene autoleucel or cilta-cel) as a treatment for adults with relapsed and refractory multiple myeloma who have received at least three prior therapies and whose cancer is worsening.

Antibody 93

Antibody Clinical Trials Clinical Trials Sales 93

Advertisement

Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud

Clinical Research

JAMA Internal Medicine

MARCH 27, 2022

This nationwide birth cohort study of 3.4 million children nested in nationwide health care utilization data with up to 14 years of follow-up evaluates the risk of specific neurodevelopment disorders associated with in utero exposure to antipsychotic medications.

Drugs 76

Drugs 76

pharmaphorum

MARCH 27, 2022

AstraZeneca has bought a stake in digital health firm Huma Therapeutics in a deal that will see ownership of AZ’s AMAZE disease management platform transfer to the UK startup. The two companies say they plan to launch a series of Software as a Medical Device (SaMD) companion apps for various diseases, including asthma, chronic obstructive pulmonary disease (COPD) and heart failure, as well as technology for running decentralised clinical trials.

Clinical Trials 59

Clinical Trials Clinical Trials Trials 59

The Pharma Data

MARCH 27, 2022

More than 50 percent of patients with moderate-to-severe atopic dermatitis (AD) experienced at least 75 percent reduction in disease severity (EASI-75*) at 16 weeks when receiving lebrikizumab monotherapy in the ADvocate program, Eli Lilly and Company (NYSE: LLY) announced today at the American Academy of Dermatology (AAD) Annual Meeting. Lebrikizumab, an investigational IL-13 inhibitor, also led to clinically meaningful improvements in itch and other important patient-reported outcomes compared

Dermatology 52

Dermatology Medicine Antibody Protein 52

Drug Patent Watch

MARCH 27, 2022

Annual Drug Patent Expirations for TRULANCE Trulance is a drug marketed by Salix and is included in one NDA. It is available from two suppliers. There are nine patents protecting…. The post New patent expiration for SALIX drug TRULANCE appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

The Pharma Data

MARCH 27, 2022

Adults with severe alopecia areata (AA) who took OLUMIANT ® (baricitinib) achieved significant scalp, eyelash and eyebrow hair regrowth and nearly 75% of those who responded to OLUMIANT 4-mg achieved 90% scalp coverage at 52 weeks, Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today at the American Academy of Dermatology (AAD) Annual Meeting.

Dermatology 40

Dermatology Medicine Licensing Licensing 40

Drug Patent Watch

MARCH 27, 2022

Annual Drug Patent Expirations for CLARINEX+D+24+HOUR Clarinex D 24 Hour is a drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this…. The post New patent expiration for Merck Sharp drug CLARINEX D 24 HOUR appeared first on DrugPatentWatch - Make Better Decisions.

Drugs 52

Drugs Marketing 52

Advertisement

White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations

Clinical Trials

Drug Patent Watch

MARCH 27, 2022

This chart shows the pharmaceutical companies with the most supplementary protection certificates (SPCs) in Spain. SPCs are used in European Union and select others to encourage pharmaceutical innovation by compensating…. The post Which pharmaceutical companies have the most SPCs in Spain? appeared first on DrugPatentWatch - Make Better Decisions.

52

52